A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether positron emission tomography is useful in the diagnosis and prognosis of malignant pleural mesothelioma (MPM). Altogether 136 papers were found using the reported search, of which 15 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that fluorodeoxyglucose-positron emission tomography (FDG-PET) accurately differentiates benign from malignant pleural disease, helps detect recurrence and provides prognostic information in terms of staging, survival and mortality. Eleven studies evaluated the role of FDG-PET in the diagnosis and prognosis of MPM. Malignant disease had a higher standardised uptake value (SUV) (6.5"3.4 vs. 0.8"0.6; P-0.001) than benign pleural disease. Shorter median survival (9.7 vs. 21 months; Ps0.02) was associated with high SUV ()10) than low SUV (-10). PET accurately upstaged 13% and downstaged 27% of cases initially staged with computed tomography (CT). In patients undergoing chemotherapy, higher total glycolytic volume led to a lower median survival (4.9 vs. 11.5 months; Ps0.09), while a decline in FDG uptake was associated with a longer time to tumour progression (14 vs. 7 months; Ps0.02). Four studies observed the role of FDG-PET-CT in the diagnosis and prognosis of MPM. SUV was found to be higher in MPM compared to benign pleural disease (6.5 vs. 0.8; P-0.001). A higher SUV was max observed in primary pleural lesions of metastatic (7.1 vs. 4.7; Ps0.003) compared to non-metastatic disease. Patients who underwent surgery had equivalent survival to those excluded based on scan results (20 vs. 12 months; Ps0.3813). One study compared the utility of PET and PET-CT in the diagnosis and prognosis of mesothelioma. PET-CT was found to be more accurate than PET in terms of staging (P-0.05) disease. Overall, PET accurately diagnoses MPM, predicts survival and disease recurrence. It can guide further management by predicting the response to chemotherapy and excluding surgery in patients with extrathoracic disease. Combined PET-CT has additional benefits in accurately staging disease.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients with malignant pleural mesotheliomax is wpositron emission tomographyx superior to wcomputed tomography or magnetic resonance imagingx in terms of wdiagnostic, staging and prognostic data providedx.
Clinical scenario
You are at a multidisciplinary meeting and review a 55-year-old male with a confirmed histological diagnosis of malignant pleural mesothelioma (MPM). You are asked whether positron emission tomography (PET) would provide *Corresponding author. Tel.: q44-75-15542899; fax: q44-20-71881016 . E-mail address: marco.scarci@mac.com (M. Scarci).
additional diagnostic or prognostic information. You are unsure about the extent to which PET may have a role and resolve to check the literature yourself.
Search strategy
Medline search 1950 to August 2010 was performed using OVIDSP interface.
(exp MesotheliomayOR mesothelioma.mp) AND (exp Positron-Emission TomographyyOR positron emission tomography.mp. or PET.mp)
Search outcome
One hundred and thirty-six papers were found using the reported search. From these, 15 papers provided the best evidence to answer the question. These are presented in Table 1 . In addition, the reference list of each paper was searched. 
Results
Eleven studies evaluated the role of PET in MPM. Mavi et al. w2x reported greater 18F-fluorodeoxyglucose (FDG) uptake over time with both primary MPM (DSUV s12.8" max 8.4%) and recurrent MPM (DSUV s13.8"9.2%) but lower max uptake in benign pleural disease (DSUV s-9.6"19.1%). observed large increases in delayed (120 min post-18F-FDG injection) compared to early (60 min post-18F-FDG injection) standardised uptake valve (SUV) measurements in malignant (7.72"6.08 vs. 9.39"7.70, P-0.001) but not in benign disease (2.92"2.45 vs. 3.27"3.26, PsNS). Mean SUV was higher in malignant disease (P-0.01). MPM was detected with a sensitivity, specificity and overall accuracy of 88%. Flores w4x observed higher SUV in N2 disease (8.6"3.4) than N0-N1 disease (5.3"2.1). The area under the receiver operating curve (AUC) of SUV was a strong predictor of N2 disease (78"10%). SUV of -4 was associated with a longer survival than a SUV of )4 (24 vs. 14 months; P-0.04), with the latter having a hazard ratio (HR) for death of 3.3 (Ps0.03). In 2006, Flores et al. w5x assessed survival in 137 patients with MPM over seven years. A high SUV ()10) was associated with a shorter survival (9.7 vs. 21 months; Ps0.02) and 1.9 times greater death risk (P-0.01) than low SUV (-10).
Bernard et al. w6x analysed 22 patients with MPM and reported higher mean SUV in deceased patients (6.6"2.9 vs. 3.2"1.6) compared to those that survived. The cumulative survival at 12 months in patients who had high SUVs ()4.03) was lower than those who had a low SUV (F4.03) (17% vs. 86%; P-0.01). Nowak et al. w7x reported PET to be a significant predictor of survival (Ps0.008) in patients with MPM and SUV to trend towards significance only max (Ps0.055). Ceresoli et al. w8x evaluated response to chemotherapy using FDG-PET. Responders (G25% reduction in FDG uptake) had a longer median time to tumour progression (14 vs. 7 months; Ps0.02) and longer survival (Ps0.07) than non-responders. Similarly, Francis et al. w9x observed the role of serial 18F-FDG-PET in assessing the response to chemotherapy after one cycle. Patients with a partial response had a lower median total glycolytic volume (TGV) (30% vs. 71% of baseline) compared to those with stable disease. Reduction in TGV was predictive of improved survival (Ps0.015). Nanni et al. w10x compared 18F-FDG-PET to computed tomography (CT) and found 60% concordance in staging disease. However, 13% of patients were upstaged and 27% downstaged by PET, leading to a change in management in 20%. Yan et al. w11x reported greater 18-month survival in patients with preoperative compared to postoperative FDG-PET (45% vs. 26%;
P-0.012).
Four studies evaluated the combination of PET-CT in the diagnosis and prognosis of mesothelioma. Wilcox et al. w12x observed that 13 patients were upstaged following the use of PET-CT. There was no significant difference in survival between patients who had extrapleural pneumonectomy (ns8) and those excluded from surgery based on scan results (ns14) (20 vs. 12 months; Ps0.3812) . Yildrim et al. w13x reported 18F-FDG-PET-CT detected MPM (ns17) and benign pleural disease (ns14) with high sensitivity (88.2%), specificity (92.9%) and overall accuracy (90.3%). The mean SUV was higher in MPM than benign pleural max disease (6.5"3.4 vs. 0.8"0.6; P-0.001) . Lee et al. w14x detected metastases in nine patients with MPM of which eight had previously been undetected. The primary pleural lesions in patients with metastases had higher mean SUV (7.1 vs. 4.7; Ps0.003) and shorter survival (four vs. max eight months; P-0.05) than those of non-metastatic disease. Recently, Tan et al. w15x reported the use of 18F-FDG-PET-CT in diagnosing disease recurrence postmultimodality therapy for MPM. Seventeen of 18 cases were detected (sensitivity 94%) and in seven patients no recurrence was identified (specificity 100%). The mean SUV max of recurrent disease was 8.9"4.0.
One study compared the accuracies of PET and PET-CT in diagnosing and staging MPM. In 2008, Plathow et al. w16x analysed the accuracy of PET in staging 54 patients with epithelial MPM. For stage II disease PET had an accuracy of 86% with sensitivity and specificity of 100% and 84.6%, respectively. For stage III disease, PET had similar accuracy of 83% with sensitivity and specificity of 83% and 100%, respectively. PET-CT was found to be more accurate than PET (P-0.05) and was observed to have 100% sensitivity and specificity for all disease stages.
Clinical bottom line
PET is useful diagnostic tool to identify and stage MPM and differentiate it from benign pleural disease. The above studies have found PET to be useful in the prediction of survival, determination of mortality risk and detection of metastases and recurrent disease. However, the combination of PET-CT produced superior diagnostic results than PET alone, highlighting the need for further prospective studies to refine the role of PET and PET-CT in different settings of MPM. There are many diagnostic modalities to identify patients with MPM. Currently, there is no consensus as to which single modality should be used to confirm diagnosis prior to surgery. Increasingly, PET-CT is playing a crucial role in the assessment of patients with known or suspected MPM due to its capacity for: 1. differentiation from benign pleural diseases, 2. high sensitivity in preoperative staging for the selection of appropriate surgical candidates, 3. post-treatment surveillance for recurrence, 4. evaluation of therapeutic response.
PET-CT seems to be superior to other imaging modalities in detecting more extensive disease involvement, and in identifying unsuspected occult distant metastases. However, surgical or radiological pleural biopsy still provides the most accurate definitive diagnosis in MPM, as reported by the authors themselves in another published paper w2x, although it is a more invasive procedure than PET-CT. If indeed it is true that PET-CT increases the accuracy of overall staging in patients with MPM and significantly improves the selection of patients for curative surgical resection, it is also true that histological confirmation is required and mandatory due to the evidence that histological subtype is an established prognostic factor in malignant pleural mesothelioma w3x. The current diagnostic gold standard is principally based on light microscopic examination of hematoxylin-eosin and immunohistochemical stains of large tissue sections or cellular tissue. Indeed pathological diagnosis of MPM and classification of histological findings into one of the three subtypes (epithelial, sarcomatoid, biphasic) are necessary to evaluate the impact on prognosis.
In conclusion, to achieve accurate diagnosis of MPM, obtaining cellular or large tissue samples in the initial examination is recommended. The integration of PET-CT and biopsy offers the best way to diagnose and stage MPM.
